NCT05687136 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited